Advanced Filters
noise

Pico Rivera, California Clinical Trials

A listing of Pico Rivera, California clinical trials actively recruiting patient volunteers.

Found 718 clinical trials
Z Zhanghua Chen, PhD

HEPA, PM2.5, and Cardiometabolic Health

The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.

65 - 84 years of age All Phase N/A
G Galvani Operations Director

ConsideRAte Study - Splenic Stimulation for RA

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open …

22 - 75 years of age All Phase N/A
S Sophie Miller

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

18 years of age All Phase 1
S Site Public Contact

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …

18 years of age All Phase 2/3

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

18 years of age All Phase 1/2
T Theodore Yuo, MD

Comparing Surgical and Endovascular Arteriovenous Fistula Creation

Patients with end-stage kidney disease (ESKD) who use hemodialysis to filter their blood require vascular access for the dialysis machine; the most common type of vascular access is called an arteriovenous fistula (AVF). The AVF is a direct connect between an artery and vein. Until recently, AVFs were only created …

18 - 99 years of age All Phase N/A
W Wayne Feng, MD

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are …

18 years of age All Phase 2
A Associate Director for Clinical Research

Study of FID-022 in Participants With Advanced Solid Tumors

The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

18 years of age All Phase 1
B Bria Bartsch, OT

EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields …

22 - 80 years of age All Phase N/A

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.

years of age All Phase 3

Simplify language using AI